Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor type that is
typically metastatic upon diagnosis. We have a poor understanding of the factors that control …

Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective
treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and …

Metastasis is a major cause of morbidity and mortality in patients with cancer, highlighting
the need to identify improved treatment and prevention strategies. Previous observations in …

Small cell lung cancer (SCLC) is an aggressive cancer often diagnosed after it has
metastasized. Despite the need to better understand this disease, SCLC remains poorly …

Small cell lung cancer (SCLC) is the most deadly subtype of lung cancer due to its dismal
prognosis. We have developed a lentiviral vector-mediated SCLC mouse model and have …

Small cell lung cancer (SCLC) exhibits insulin-like growth factor-dependent growth. SCLC is
the most aggressive among known in vivo lung cancers, whereas in vitro growth of SCLC is …

The discovery of recurrent alterations in genes encoding transcription regulators and
chromatin modifiers is one of the most important recent developments in the study of the …

Small cell lung cancer (SCLC) is a highly aggressive human tumor with a more than 95%
mortality rate. Its ontogeny and molecular pathogenesis remains poorly understood. We …

The coactivator associated arginine methyltransferase (CARM1) promotes transcription, as
its name implies. It does so by modifying histones and chromatin bound proteins. We …

Emerging evidence indicates that nuclear factor I/B (NFIB), a transcription factor required for
proper development and regulation of cellular differentiation in several tissues, also plays …